News and Announcements
Shivom Raises $33 Million, Nearly Reaching Their Goal of $35 Million!
- Published April 25, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
- Shivom raised $33 million during the course of our private and publicpresales
- Shivom is $2 million away from achieving the target cap
- Their public presale is still open and the bonus has been locked at 3% until the sale closes on Friday, April 27th, 6 PM GMT
We have exciting news to share with our community.
Shivom has raised $33 million during the course of our private and publicpresales, and is only $2 million away from achieving the target cap of $35 million. This is HUGE for us, and we cannot thank our contributors and partners enough for supporting us along the way.
CONSIDERING THAT, WE HAVE REMOVED THE MINIMUM CAP ON INVESTMENT FOR THE PRESALE NOW.
Our public presale is still open and the bonus has been locked at 3% until the sale closes on Friday, April 27th, 2018, 6 PM GMT. This is the last chance to make use of the available bonuses if you are still contemplating your contribution to join the Shivom community. Don’t miss your chance to be part of a global healthcare revolution.
To register, sign up at: https://tokensale.shivom.io/
KYC verification can take some time. However, please complete your purchase of OMIX tokens now. You’ll have enough time to complete your KYC verification post the Presale.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
